Buy XENE Ahead of Azetukalner NDA - Approval Is the Binary Upside, Commercial Runway Looks Solid
Xenon Pharmaceuticals' positive Phase 3 X-TOLE2 results and planned New Drug Application submission in Q3 2026 make XENE a strong buy for investors willing to take a binary biotech trade. The company has backed efficacy data (53.2% median seizure reduction at 25 mg vs 10.4% for placebo), a sizable $650M capital raise, and a market cap near $6.3B. T…